phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

Newly released pharmacy benefit manager (PBM) data show medicine spending is growing at the slowest rate in years. After accounting for discounts and rebates negotiated with biopharmaceutical companies, PBMs report that medicine spending growth in 2017 was in the low single digits or slightly negative.

So where do the discounts go? 

A previous analysis by the Berkeley Research Group found brand biopharmaceutical companies retained just 63 percent of the list price for brand medicines. The rest – nearly 40 percent – is rebated back to insurance companies, PBMs and the government, or retained by other stakeholders in the supply chain. These discounts and rebates create savings of more than $100 billion, but insurers don’t always share these savings with patients who are facing rising out-of-pocket costs when they go to the pharmacy to get their medicine.  

Patients share the costs. They should share the savings. 

Learn more at LetsTalkAboutCost.org.

Holly Campbell

Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines.

Holly Campbell

Author Twitter

Author LinkedIn

What AARP isn’t telling seniors about MFN

August 24, 2026

Policymakers should improve patient access and reject price controls

August 18, 2026

CMS proposal could discourage patient-centered innovation

August 18, 2026

Insurers blame GLP-1s for rising costs. The data tells a different story.

August 14, 2026

ICYMI – Two PBM reports show dramatic slowdown in medicine spending growth

Drug Cost

Medicaid

Medicare

Out-of-Pocket Costs

Part D

PBMs/Insurance

Lets Talk About Cost

ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth

March 2, 2018

ICYMI – Two PBM reports show dramatic slowdown in medicine spending growth

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list